Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-L19SIP plus whole brain radiotherapy for multiple brain metastases from solid tumors
2009-013002-13Phase 2Completed
- Sponsor
- Philogen
- Start
- Jul 2009
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 131I-radretumab in brain metastases and Nonhematologic neoplasms, sponsored by Philogen. Primary endpoints: Selective uptake of 131I-L19SIP or 124I-L19SIP in brain lesions and Safety of combined administration of 131I-L19SIP and WBRT. Started Jul 2009; status: completed.
02
Drugs
131I-radretumab
03
Conditions
brain metastasesNonhematologic neoplasms
Beyond the preview
Go deeper on 2009-013002-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013002-13.